CAM
CRNX icon

Connacht Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Connacht Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$217K Sell
7,295
-5,111
-41% -$105K 1.29% 43
2023
Q2 		$224K Sell
12,406
-985
-7% -$19.6K 0.76% 89
2023
Q1 		$215K Buy
13,391
+1,054
+9% +$19.5K 0.62% 130
2022
Q4 		$226K Sell
12,337
-2,786
-18% -$49.1K 0.46% 106
2022
Q3 		$297K Buy
15,123
+3,842
+34% +$78.3K 0.56% 98
2022
Q2 		$210K Buy
+11,281
New +$225K 0.3% 142

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return